Lumiera Health Inc.

Equities

NHP

CA5502541066

Pharmaceuticals

Delayed Toronto S.E. 09:30:00 2022-12-08 am EST 5-day change 1st Jan Change
0.005 CAD -.--% Intraday chart for Lumiera Health Inc. -.--% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lumiera Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023 CI
Lumiera Health Inc. Appoints Mr. Shawn Moniz to the Board of Directors CI
Lumiera Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023 CI
Lumiera Health Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023 CI
Lumiera Health Inc. Reports Earnings Results for the Full Year Ended November 30, 2022 CI
Lumiera Health Inc. Auditor Raises 'Going Concern' Doubt CI
Lumiera Health Inc. Announces Board Resignations CI
Lumiera Health Inc. announced that it expects to receive CAD 0.6 million in funding CI
Lumiera Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022 CI
Lumiera Signs MOU with Natural Health Industry Company for Strategic Partnership, Licensing Agreement MT
Lumiera Enters MOU with Natural Health Industry Leader for Strategic Partnership and Licensing Agreement CI
Lumiera Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022 CI
Lumiera Health Launches US Sales of Awaye Pain Relief Cream MT
Lumiera Health Inc. Launches Awaye Pain Relief Cream in the US Market CI
Lumiera Health Inc. Reports Sales Results for the Second Quarter 2022 CI
Lumiera Health Expands Retail Footprint of Awaye™ Pain Relief Across Quebec with Sobeys' Rachelle Béry CI
Lumiera Health Seeks Health Canada Approval for a Menthol Version of Its Awaye Pain Relief Brand MT
Lumiera Health Inc. Files New NPN Application with Health Canada to Extend Awaye Pain Relief Product Line CI
Lumiera Health Inc. announced that it expects to receive CAD 0.15 million in funding from Fiducie De La Maison Bleue CI
Lumiera Health Inc. Reports Earnings Results for the First Quarter Ended February 28, 2022 CI
Lumiera Health Expands Online Distribution, Says Sleep-Aids Now Available on Amazon and Well.ca MT
Lumiera Health Inc Expands Online Distribution with Bazzzics™ Sleep-Aids on Amazon and Well.Ca CI
Lumiera Health Signs Distribution Agreement to Launch Pain Relief Medication Awaye in Vietnam MT
Lumiera Health Inc. Signs Distribution Agreement to Launch Awaye™ in Vietnam CI
Lumiera Health Inc. Reports Earnings Results for the Full Year Ended November 30, 2021 CI
Chart Lumiera Health Inc.
More charts
Lumiera Health Inc. is a Canada-based natural health products company. The principal business of the Company is that of selling natural and homeopathic products. The Company specializes in the development and commercialization of evidence-based botanical products for the healthcare industry. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. It is also developing and commercializing a portfolio of innovative solutions in high growth categories such as sleep-aids and pain management. Its product's portfolio categories such as topical pain relief, sleep, skin care, women's health, & infections. The Company’s products and brands include Holizen, Awaye pain relief cream and Bazzzics. The Holizen portfolio has over 20 products that cover a range of therapeutic needs, including cardiovascular health; stress relief; bones, joints & muscle mobility; energy and immunity.
More about the company
  1. Stock Market
  2. Equities
  3. NHP Stock
  4. News Lumiera Health Inc.
  5. Lumiera Health : Announces CEO Appointment